Lecanemab Shows Strong Long-Term Patient Retention in Real-World Use
Event summary
- 94% of patients who completed 18 months of lecanemab treatment in the Phase III Clarity AD study chose to continue maintenance treatment.
- Real-world data shows 78.4% of patients continued lecanemab treatment at 18 months, 71.7% at 20 months, and 67.3% at 24 months.
- Lecanemab has been approved in 53 countries and regions, with ongoing regulatory reviews in 6 additional countries.
- The U.S. FDA granted Priority Review for lecanemab's subcutaneous maintenance dosing, with a PDUFA action date of May 24, 2026.
The big picture
The strong long-term treatment persistence of lecanemab underscores its potential as a durable therapy for Alzheimer's disease. This data comes at a critical time as Biogen and Eisai seek to expand the drug's regulatory approvals and commercial reach. The collaboration between Eisai and Biogen, along with their strategic partnerships, positions lecanemab as a key player in the evolving landscape of Alzheimer's treatment.
What we're watching
- Regulatory Milestones
- The pace at which lecanemab's subcutaneous formulation gains regulatory approvals in additional countries will impact its commercial potential.
- Market Competition
- Whether Biogen and Eisai can sustain lecanemab's market position amid potential competition from other anti-amyloid therapies.
- Long-Term Efficacy
- How the long-term efficacy and safety data of lecanemab will influence its adoption in real-world clinical practice.
Related topics